Matinas BioPharma (MTNB) Begins ENHANCE-IT Study of MAT9001 Against Vascepa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. SKA-B
5. PBA
6. CCH:LN
7. META
8. CCHGY
9. PRY:IM
10. PRYMY

Go back to Matinas BioPharma (MTNB) Begins ENHANCE-IT Study of MAT9001 Against Vascepa

Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®

March 5, 2020 7:00 AM EST

Topline data expected Q4 2020

BEDMINSTER, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has initiated the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a head-to-head pharmacodynamic (PD) study of MAT9001 against... More